A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-08

AUTHORS

Emma K. Beardsley, Sebastien J. Hotte, Scott North, Susan L. Ellard, Eric Winquist, Christian Kollmannsberger, Som D. Mukherjee, Kim N. Chi

ABSTRACT

PURPOSE: The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-targeted kinase inhibitor, in combination with androgen receptor blockade in patients with castration-resistant prostate cancer. METHODS: This was a multicenter, two-stage, phase 2 trial. Eligible patients had rising PSA, minimal symptoms and were chemotherapy-naïve. Sorafenib 400 mg twice daily was administered with bicalutamide 50 mg once daily on a 28-day cycle. The primary endpoint was PSA response (≥ 50% decline) or stable disease ≥ 6 months. RESULTS: 39 patients were enrolled including eight without clinical evidence of metastases. Eighteen (47%) patients have had either a PSA response or stable disease ≥ 6 months. PSA declines of ≥ 50% occurred in 12 (32%) of 38 assessable patients, including seven of 27 patients (26%) with prior anti-androgen use. Median time to treatment failure was 5.5 months (95%CI = 4.8.1-8.3). Grade ≥ 3 adverse events included fatigue, skin rash, and hand-foot syndrome. CONCLUSIONS: PSA declines and stable disease were observed with a combination of sorafenib and bicalutamide including in patients previously progressing on bicalutamide. Strategies to combine multi-targeted kinase inhibitors with hormonal therapies warrant further study in patients with CRPC. More... »

PAGES

1652-1659

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-011-9722-5

DOI

http://dx.doi.org/10.1007/s10637-011-9722-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034871441

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21785998


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzenesulfonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Orchiectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tosyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency \u2013 Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beardsley", 
        "givenName": "Emma K.", 
        "id": "sg:person.0672204513.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672204513.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Juravinski Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.477522.1", 
          "name": [
            "Juravinski Cancer Centre, Hamilton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hotte", 
        "givenName": "Sebastien J.", 
        "id": "sg:person.01116377030.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116377030.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Alberta", 
          "id": "https://www.grid.ac/institutes/grid.17089.37", 
          "name": [
            "Cross Cancer Institute, Edmonton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "North", 
        "givenName": "Scott", 
        "id": "sg:person.01151470300.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151470300.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency - Cancer Centre for the Southern Interior, Kelowna, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ellard", 
        "givenName": "Susan L.", 
        "id": "sg:person.01004224136.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004224136.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "London Health Sciences Centre", 
          "id": "https://www.grid.ac/institutes/grid.412745.1", 
          "name": [
            "London Health Sciences Centre, London, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Winquist", 
        "givenName": "Eric", 
        "id": "sg:person.01031740163.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031740163.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency \u2013 Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kollmannsberger", 
        "givenName": "Christian", 
        "id": "sg:person.0660645031.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Juravinski Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.477522.1", 
          "name": [
            "Juravinski Cancer Centre, Hamilton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukherjee", 
        "givenName": "Som D.", 
        "id": "sg:person.01237110113.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237110113.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency \u2013 Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Kim N.", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)60172-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009261099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1476-4598-9-107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010978668", 
          "https://doi.org/10.1186/1476-4598-9-107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1001294", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017807249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1014618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018044872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0090-4295(01)01010-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019718764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(10)72113-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020409352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2010.05.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028349062"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2008.05.045", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029018822"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa040720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029249997"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.06.037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033762535"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-1355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034674125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm554", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035066248"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/94.19.1458", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035900290"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038009239", 
          "https://doi.org/10.1038/nm.2166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038009239", 
          "https://doi.org/10.1038/nm.2166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35094009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041216924", 
          "https://doi.org/10.1038/35094009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35094009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041216924", 
          "https://doi.org/10.1038/35094009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)64039-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041774655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0708857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053513212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.11.3461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074545753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.1.62", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074743425"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074795197", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074847503", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075104066", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075271973", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.4510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083943311"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-08", 
    "datePublishedReg": "2012-08-01", 
    "description": "PURPOSE: The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-targeted kinase inhibitor, in combination with androgen receptor blockade in patients with castration-resistant prostate cancer.\nMETHODS: This was a multicenter, two-stage, phase 2 trial. Eligible patients had rising PSA, minimal symptoms and were chemotherapy-na\u00efve. Sorafenib 400 mg twice daily was administered with bicalutamide 50 mg once daily on a 28-day cycle. The primary endpoint was PSA response (\u2265 50% decline) or stable disease \u2265 6 months.\nRESULTS: 39 patients were enrolled including eight without clinical evidence of metastases. Eighteen (47%) patients have had either a PSA response or stable disease \u2265 6 months. PSA declines of \u2265 50% occurred in 12 (32%) of 38 assessable patients, including seven of 27 patients (26%) with prior anti-androgen use. Median time to treatment failure was 5.5 months (95%CI\u2009=\u20094.8.1-8.3). Grade \u2265 3 adverse events included fatigue, skin rash, and hand-foot syndrome.\nCONCLUSIONS: PSA declines and stable disease were observed with a combination of sorafenib and bicalutamide including in patients previously progressing on bicalutamide. Strategies to combine multi-targeted kinase inhibitors with hormonal therapies warrant further study in patients with CRPC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-011-9722-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "name": "A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer", 
    "pagination": "1652-1659", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a61d714c625a97eddc412383b71dbe56d4e515146207fda69fd5edf8f60113d0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21785998"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-011-9722-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034871441"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-011-9722-5", 
      "https://app.dimensions.ai/details/publication/pub.1034871441"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-011-9722-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9722-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9722-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9722-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9722-5'


 

This table displays all metadata directly associated to this object as RDF triples.

288 TRIPLES      21 PREDICATES      76 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-011-9722-5 schema:about N06e7589472fb4e6fa4c4deac911906e9
2 N12b05c2c3aba4b6d8bce770adcacac38
3 N29b62068462d4d3ab0311c96f09a9930
4 N2ae829d86c2a4190a15bafc2a855dddf
5 N355fd1933d7a4b49b090b32ae28962cc
6 N377e82fb6f274feba7cfbecfdcc2fb6c
7 N45d1f440694c4c75984320b58f4e8ee7
8 N63ef441398b348839d2210182e02ce56
9 N7864f075f1254c81815c4e4f8103340c
10 N7d6fd845f74441c79858c0d8906cbdd4
11 N7f1483c408d543e4a7186d3bd38fef4a
12 N7fc4d2cdae844e2d9569295eaa4e0cb3
13 N970bb0be6395466fa078fad77b4fe8ed
14 Na1b60f39ac104d91a9922be1ebd5116a
15 Nb1abe16b72f74fd38954b2d88a1d5109
16 Ncc30de41ec954dc68125792f8c746b91
17 Ncfb8778a419a42119cdf784448ac0131
18 Ne65d40290d174fffb92fc1186a306a4c
19 Nf0a3619abecf4c22a29f75d3b3838cec
20 Nf865d05dc6344fc8bc6e9df974708556
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N6d24b77492ce4fea82f68997f437a473
24 schema:citation sg:pub.10.1038/35094009
25 sg:pub.10.1038/nm.2166
26 sg:pub.10.1186/1476-4598-9-107
27 https://app.dimensions.ai/details/publication/pub.1074795197
28 https://app.dimensions.ai/details/publication/pub.1074847503
29 https://app.dimensions.ai/details/publication/pub.1075104066
30 https://app.dimensions.ai/details/publication/pub.1075271973
31 https://doi.org/10.1016/0197-2456(89)90015-9
32 https://doi.org/10.1016/j.ccr.2010.05.026
33 https://doi.org/10.1016/j.juro.2008.05.045
34 https://doi.org/10.1016/s0022-5347(01)64039-4
35 https://doi.org/10.1016/s0090-4295(01)01010-x
36 https://doi.org/10.1016/s0140-6736(10)60172-9
37 https://doi.org/10.1016/s1359-6349(10)72113-3
38 https://doi.org/10.1056/nejmoa040720
39 https://doi.org/10.1056/nejmoa060655
40 https://doi.org/10.1056/nejmoa0708857
41 https://doi.org/10.1056/nejmoa1001294
42 https://doi.org/10.1056/nejmoa1014618
43 https://doi.org/10.1093/annonc/mdm554
44 https://doi.org/10.1093/jnci/92.3.205
45 https://doi.org/10.1093/jnci/94.19.1458
46 https://doi.org/10.1158/1078-0432.ccr-07-1355
47 https://doi.org/10.1200/jco.1999.17.11.3461
48 https://doi.org/10.1200/jco.2001.19.1.62
49 https://doi.org/10.1200/jco.2004.06.037
50 https://doi.org/10.1200/jco.2010.28.15_suppl.4510
51 schema:datePublished 2012-08
52 schema:datePublishedReg 2012-08-01
53 schema:description PURPOSE: The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-targeted kinase inhibitor, in combination with androgen receptor blockade in patients with castration-resistant prostate cancer. METHODS: This was a multicenter, two-stage, phase 2 trial. Eligible patients had rising PSA, minimal symptoms and were chemotherapy-naïve. Sorafenib 400 mg twice daily was administered with bicalutamide 50 mg once daily on a 28-day cycle. The primary endpoint was PSA response (≥ 50% decline) or stable disease ≥ 6 months. RESULTS: 39 patients were enrolled including eight without clinical evidence of metastases. Eighteen (47%) patients have had either a PSA response or stable disease ≥ 6 months. PSA declines of ≥ 50% occurred in 12 (32%) of 38 assessable patients, including seven of 27 patients (26%) with prior anti-androgen use. Median time to treatment failure was 5.5 months (95%CI = 4.8.1-8.3). Grade ≥ 3 adverse events included fatigue, skin rash, and hand-foot syndrome. CONCLUSIONS: PSA declines and stable disease were observed with a combination of sorafenib and bicalutamide including in patients previously progressing on bicalutamide. Strategies to combine multi-targeted kinase inhibitors with hormonal therapies warrant further study in patients with CRPC.
54 schema:genre research_article
55 schema:inLanguage en
56 schema:isAccessibleForFree false
57 schema:isPartOf N286d6056b8b54295adbc9422690fdb79
58 Ndf29e19afbe541abbe54d975185521b0
59 sg:journal.1094201
60 schema:name A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
61 schema:pagination 1652-1659
62 schema:productId N16159f85e70444a4bd1ee6c636fb953d
63 N3695170e80c142b6a27d669daa343086
64 N3d406096691b4aa4b8b3556fd996f122
65 Nb77aafb45d704f858ab4a8b4bb52025f
66 Nfe4b4437c5884ab58e21f983c83718c7
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034871441
68 https://doi.org/10.1007/s10637-011-9722-5
69 schema:sdDatePublished 2019-04-10T14:10
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N6e0d06fb50664cc89b8494bec01a285b
72 schema:url http://link.springer.com/10.1007%2Fs10637-011-9722-5
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N06e7589472fb4e6fa4c4deac911906e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Tosyl Compounds
78 rdf:type schema:DefinedTerm
79 N12b05c2c3aba4b6d8bce770adcacac38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Humans
81 rdf:type schema:DefinedTerm
82 N16159f85e70444a4bd1ee6c636fb953d schema:name nlm_unique_id
83 schema:value 8309330
84 rdf:type schema:PropertyValue
85 N286d6056b8b54295adbc9422690fdb79 schema:issueNumber 4
86 rdf:type schema:PublicationIssue
87 N29b62068462d4d3ab0311c96f09a9930 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Antineoplastic Agents
89 rdf:type schema:DefinedTerm
90 N2ae829d86c2a4190a15bafc2a855dddf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Treatment Failure
92 rdf:type schema:DefinedTerm
93 N355fd1933d7a4b49b090b32ae28962cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Anilides
95 rdf:type schema:DefinedTerm
96 N3695170e80c142b6a27d669daa343086 schema:name readcube_id
97 schema:value a61d714c625a97eddc412383b71dbe56d4e515146207fda69fd5edf8f60113d0
98 rdf:type schema:PropertyValue
99 N377e82fb6f274feba7cfbecfdcc2fb6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Benzenesulfonates
101 rdf:type schema:DefinedTerm
102 N3d406096691b4aa4b8b3556fd996f122 schema:name doi
103 schema:value 10.1007/s10637-011-9722-5
104 rdf:type schema:PropertyValue
105 N45d1f440694c4c75984320b58f4e8ee7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Antineoplastic Combined Chemotherapy Protocols
107 rdf:type schema:DefinedTerm
108 N63ef441398b348839d2210182e02ce56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Aged
110 rdf:type schema:DefinedTerm
111 N6d24b77492ce4fea82f68997f437a473 rdf:first sg:person.0672204513.24
112 rdf:rest Nff35d797917a41b7afe5158b6b4fe282
113 N6e0d06fb50664cc89b8494bec01a285b schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N7864f075f1254c81815c4e4f8103340c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Aged, 80 and over
117 rdf:type schema:DefinedTerm
118 N7d6fd845f74441c79858c0d8906cbdd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Prostatic Neoplasms
120 rdf:type schema:DefinedTerm
121 N7f1483c408d543e4a7186d3bd38fef4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Phenylurea Compounds
123 rdf:type schema:DefinedTerm
124 N7fc4d2cdae844e2d9569295eaa4e0cb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Pyridines
126 rdf:type schema:DefinedTerm
127 N970bb0be6395466fa078fad77b4fe8ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Nitriles
129 rdf:type schema:DefinedTerm
130 N9d96459b5109452fb15c0eec74e1486f rdf:first sg:person.01151470300.91
131 rdf:rest Nb562f09326664b0095055ab88d0bf08f
132 Na0c4ac50b3814cad8e492b9f075c7aca rdf:first sg:person.01031740163.39
133 rdf:rest Ne27a009d3b4446f8a9ff6173dcf478e6
134 Na1b60f39ac104d91a9922be1ebd5116a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Male
136 rdf:type schema:DefinedTerm
137 Na79610211b7f4f6794342bf129217fcf rdf:first sg:person.01142252161.65
138 rdf:rest rdf:nil
139 Nb1abe16b72f74fd38954b2d88a1d5109 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Orchiectomy
141 rdf:type schema:DefinedTerm
142 Nb34063b7308c4d9588db1123e9c59ff2 rdf:first sg:person.01237110113.33
143 rdf:rest Na79610211b7f4f6794342bf129217fcf
144 Nb562f09326664b0095055ab88d0bf08f rdf:first sg:person.01004224136.10
145 rdf:rest Na0c4ac50b3814cad8e492b9f075c7aca
146 Nb77aafb45d704f858ab4a8b4bb52025f schema:name dimensions_id
147 schema:value pub.1034871441
148 rdf:type schema:PropertyValue
149 Ncc30de41ec954dc68125792f8c746b91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Niacinamide
151 rdf:type schema:DefinedTerm
152 Ncfb8778a419a42119cdf784448ac0131 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Kaplan-Meier Estimate
154 rdf:type schema:DefinedTerm
155 Ndf29e19afbe541abbe54d975185521b0 schema:volumeNumber 30
156 rdf:type schema:PublicationVolume
157 Ne27a009d3b4446f8a9ff6173dcf478e6 rdf:first sg:person.0660645031.33
158 rdf:rest Nb34063b7308c4d9588db1123e9c59ff2
159 Ne65d40290d174fffb92fc1186a306a4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Middle Aged
161 rdf:type schema:DefinedTerm
162 Nf0a3619abecf4c22a29f75d3b3838cec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Prostate-Specific Antigen
164 rdf:type schema:DefinedTerm
165 Nf865d05dc6344fc8bc6e9df974708556 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Time Factors
167 rdf:type schema:DefinedTerm
168 Nfe4b4437c5884ab58e21f983c83718c7 schema:name pubmed_id
169 schema:value 21785998
170 rdf:type schema:PropertyValue
171 Nff35d797917a41b7afe5158b6b4fe282 rdf:first sg:person.01116377030.40
172 rdf:rest N9d96459b5109452fb15c0eec74e1486f
173 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
174 schema:name Medical and Health Sciences
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
177 schema:name Clinical Sciences
178 rdf:type schema:DefinedTerm
179 sg:journal.1094201 schema:issn 0167-6997
180 1573-0646
181 schema:name Investigational New Drugs
182 rdf:type schema:Periodical
183 sg:person.01004224136.10 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
184 schema:familyName Ellard
185 schema:givenName Susan L.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004224136.10
187 rdf:type schema:Person
188 sg:person.01031740163.39 schema:affiliation https://www.grid.ac/institutes/grid.412745.1
189 schema:familyName Winquist
190 schema:givenName Eric
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031740163.39
192 rdf:type schema:Person
193 sg:person.01116377030.40 schema:affiliation https://www.grid.ac/institutes/grid.477522.1
194 schema:familyName Hotte
195 schema:givenName Sebastien J.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116377030.40
197 rdf:type schema:Person
198 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
199 schema:familyName Chi
200 schema:givenName Kim N.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
202 rdf:type schema:Person
203 sg:person.01151470300.91 schema:affiliation https://www.grid.ac/institutes/grid.17089.37
204 schema:familyName North
205 schema:givenName Scott
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151470300.91
207 rdf:type schema:Person
208 sg:person.01237110113.33 schema:affiliation https://www.grid.ac/institutes/grid.477522.1
209 schema:familyName Mukherjee
210 schema:givenName Som D.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237110113.33
212 rdf:type schema:Person
213 sg:person.0660645031.33 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
214 schema:familyName Kollmannsberger
215 schema:givenName Christian
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33
217 rdf:type schema:Person
218 sg:person.0672204513.24 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
219 schema:familyName Beardsley
220 schema:givenName Emma K.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672204513.24
222 rdf:type schema:Person
223 sg:pub.10.1038/35094009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041216924
224 https://doi.org/10.1038/35094009
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/nm.2166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038009239
227 https://doi.org/10.1038/nm.2166
228 rdf:type schema:CreativeWork
229 sg:pub.10.1186/1476-4598-9-107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010978668
230 https://doi.org/10.1186/1476-4598-9-107
231 rdf:type schema:CreativeWork
232 https://app.dimensions.ai/details/publication/pub.1074795197 schema:CreativeWork
233 https://app.dimensions.ai/details/publication/pub.1074847503 schema:CreativeWork
234 https://app.dimensions.ai/details/publication/pub.1075104066 schema:CreativeWork
235 https://app.dimensions.ai/details/publication/pub.1075271973 schema:CreativeWork
236 https://doi.org/10.1016/0197-2456(89)90015-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053744925
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1016/j.ccr.2010.05.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028349062
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1016/j.juro.2008.05.045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029018822
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1016/s0022-5347(01)64039-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041774655
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1016/s0090-4295(01)01010-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019718764
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/s0140-6736(10)60172-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009261099
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/s1359-6349(10)72113-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020409352
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1056/nejmoa040720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029249997
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1056/nejmoa0708857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053513212
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1056/nejmoa1001294 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017807249
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1056/nejmoa1014618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018044872
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1093/annonc/mdm554 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035066248
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1093/jnci/94.19.1458 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035900290
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1158/1078-0432.ccr-07-1355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034674125
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1200/jco.1999.17.11.3461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074545753
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1200/jco.2001.19.1.62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074743425
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1200/jco.2004.06.037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033762535
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1200/jco.2010.28.15_suppl.4510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083943311
275 rdf:type schema:CreativeWork
276 https://www.grid.ac/institutes/grid.17089.37 schema:alternateName University of Alberta
277 schema:name Cross Cancer Institute, Edmonton, Canada
278 rdf:type schema:Organization
279 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
280 schema:name BC Cancer Agency - Cancer Centre for the Southern Interior, Kelowna, Canada
281 BC Cancer Agency – Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, British Columbia, Canada
282 rdf:type schema:Organization
283 https://www.grid.ac/institutes/grid.412745.1 schema:alternateName London Health Sciences Centre
284 schema:name London Health Sciences Centre, London, Canada
285 rdf:type schema:Organization
286 https://www.grid.ac/institutes/grid.477522.1 schema:alternateName Juravinski Cancer Centre
287 schema:name Juravinski Cancer Centre, Hamilton, Canada
288 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...